Impel NeuroPharma appoints Jennifer L. Berman as VP of Marketing

Intranasal drug developer Impel NeuroPharma has announced the appointment of Jennifer L. Berman VP of Marketing.  Berman was most recently Worldwide Brand Director at Novartis Pharmaceuticals.

In December 2018, Impel announced that it had raised $67.5 million in a Series D financing round for continued development of intranasal products based on its Precision Olfactory Delivery (POD) technology.

Impel NeuroPharma President and CEO Jon Congleton said, “We are delighted to welcome Jennifer to the Impel team as we continue to advance our mid-to-late stage CNS assets focused on migraine, Parkinson’s disease and agitation. Jennifer’s expertise in US and global marketing, including launching major CNS brands, makes her an outstanding addition to our growing team.”

Berman commented, “I believe Impel’s exciting new approach to treating serious CNS diseases with significant unmet needs via the POD technology platform represents an opportunity to bring desired clinical outcomes to patients. I am thrilled to be joining the team at such a critical point in the company’s journey to becoming a commercial-stage organization and I look forward to working closely with the migraine, Parkinson’s and mental health communities.”

Read the Impel NeuroPharma press release.